Staar Surgical Co (NAS:STAA)
$ 40.94 -0.22 (-0.53%) Market Cap: 2.01 Bil Enterprise Value: 1.81 Bil PE Ratio: 132.06 PB Ratio: 5.09 GF Score: 89/100

STAAR Surgical Co Investor and Analyst Day Transcript

Nov 08, 2019 / 01:30PM GMT
Release Date Price: $35.5 (-1.69%)
Caren L. Mason
STAAR Surgical Company - CEO, President & Director

Thank you very much. Welcome, everyone. It's our pleasure today to host our Investor and Analyst Day. This is our second. The last was in November of 2017. Our goal today is to give you a look at where we've come from. But more importantly, most of our time will really be spent on where we're headed and why.

I'm very pleased to, today, welcome surgeons who are joining us to talk about their experience with the ICL as well as to talk about the future direction of the ICL. So you'll be hearing from them, and I will mention them during my presentation.

So the future of refractive surgery is lens-based. The time for STAAR is now. Recently, I attended our Experts Meeting and the European Society of Cataract and Refractive Surgery meeting in Paris. And while I was there, one of the most influential leaders in ophthalmology globally, Dr. John Vukich, talked to me for the first time about his new venture. He is here in the United States. You can read about his background in the material in front of you. But Dr. Vukich has

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot